Original Article

Demographic and Clinical Characteristics of a Predominantly Hispanic Population with Inflammatory Bowel Disease on the US–Mexico Border

Authors: Antonio Mendoza Ladd, MD, Yi Jia, MD, PhD, Christine Yu, MD, Sherif Elhanafi, MD, Alok Dwivedi, PhD, Jiayang Liu, MSc, Giangqing Song, MD, PhD, Mark Hall, BM, Marc J. Zuckerman, MD

Abstract

Objectives: Information regarding Hispanics with inflammatory bowel disease (IBD) is scarce. In this study we aimed to describe a predominantly Hispanic population with IBD in a city located along the US–Mexico border and to identify clinical or demographic differences between Hispanics and non-Hispanics.

Methods: Retrospective cohort analysis of patients with IBD between 2003 and 2013 at a tertiary care center. Information collected included age, sex, ethnicity, diagnosis, diagnosis status (new vs old), endoscopic extent of disease (EOD), extraintestinal manifestations, medical treatment, and surgeries performed. Continuous and categorical variables were compared using a two-sided unpaired t test/Wilcoxon rank sum test and the Fisher exact test, respectively. Results with P ≤ 5% were considered statistically significant.

Results: Hispanics accounted for 71% of the population sample. A total of 141 patients (68%) were diagnosed as having ulcerative colitis (UC) and 67 (32%) as having Crohn disease (CD). The only statistically significant differences between Hispanics and non-Hispanics were older age at diagnosis and a higher proportion of new diagnoses in Hispanics with CD ( P = 0.008 and 0.009, respectively) The most common EOD in patients with UC was extensive colitis, whereas isolated colonic disease predominated in CD, regardless of ethnicity. Immunomodulators and biologics were used in 3% and 1% of cases, respectively. Treatment regimens were similar in both ethnic groups. Patients with CD were more likely than those with UC to have undergone surgery (27% vs 11%, P = 0.004). Surgery rates did not differ between Hispanics and non-Hispanics.

Conclusions: In our population, UC was more common than CD, and the EOD of both conditions differed from the one previously described in other Hispanic populations in the United States. The use of immunomodulators and biologics is the lowest reported to date in the country. No clinically relevant differences were seen between Hispanics and non-Hispanics.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ennis S, Rios-Vargas M, Albert N. The Hispanic population: 2010. 2010 Census Briefs. http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf. Published May 2011. Accessed September 30, 2016. Commerce Do, editor: United States Census Bureau 2011.
 
2. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol 2000;15:1037-1042.
 
3. Lee YM, Fock K, See SJ, et al. Racial differences in the prevalence of ulcerative colitis and Crohn's disease in Singapore. J Gastroenterol Hepatol 2000;15:622-625.
 
4. Abdul-Baki H, ElHajj I, El-Zahabi LM, et al. Clinical epidemiology of inflammatory bowel disease in Lebanon. Inflamm Bowel Dis 2007;13:475-480.
 
5. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002;8:158-161.
 
6. Damas OM, Jahann DA, Reznik R, et al. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol 2013;108:231-239.
 
7. Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis 2004;10:106-111.
 
8. Torres EA, De Jesus R, Perez CM, et al. Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996. P R Health Sci J 2003;22:253-258.
 
9. Hou J, El-Serag H, Sellin J, et al. Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. Dig Dis Sci 2011;56:1476-1481.
 
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5A-36A.
 
11. Loftus CG, Loftus EV, Jr Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-261.
 
12. Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol 2009;43:221-224.
 
13. Bosques-Padilla FJ, Sandoval-Garcia ER, Martinez-Vazquez MA, et al. [Epidemiology and clinical characteristics of ulcerative colitis in northeastern Mexico]. Rev Gastroenterol Mex 2011;76:34–38. [Article in Spanish].
14. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis 2014;8:288-295.
 
15. Betteridge JD, Armbruster SP, Maydonovitch C, et al. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis 2013;19:1421-1427.
 
16. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
 
17. Malaty HM, Hou JK, Thirumurthi S. Epidemiology of inflammatory bowel disease among an indigent multi-ethnic population in the United States. Clin Exp Gastroenterol 2010;3:165-170.
 
18. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005;100:2254-2261.
 
19. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009;104:2100-2109.
 
20. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012-1023.
 
21. Kugathasan S, Loizides A, Babusukumar U, et al. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and white children with Crohn's disease. Inflamm Bowel Dis 2005;11:631-638.
 
22. Steinwurz F. . [Clinical experience with the use of infliximab in 44 patients with Crohn’s disease]. Arq Gastroenterol 2003;40:198–200. [Article in Portuguese].
23. van Deen WK, van Oijen MG, Myers KD, et al. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 2014;20:1747-1753.
 
24. Hattar LN, Abraham BP, Malaty HM, et al. Inflammatory bowel disease characteristics in Hispanic children in Texas. Inflamm Bowel Dis 2012;18:546-554.
 
25. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012;107:1879-1887.
 
26. Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn&#x2019s disease in population-based cohorts. Am J Gastroenterol 2010;105:289-297.